Drug
Imipenem clinical trials
- studies test it
- 30
- open now
- 4
- in phase 3
- 9
- first study started
- 2003
Keep track of what changes. Save the Imipenem studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
29 studies that test it; most in 2015 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 5
- Phase 3
- 9
- Phase 4
- 14
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 23
Merck Sharp & Dohme LLC (6) · Prince of Songkla University (3) · The University of Queensland (2) · M.D. Anderson Cancer Center (1) · Medical University of Vienna (1) · Northwestern University (1) · Juan A. Arnaiz (1) · University Hospital Rijeka (1)
Often tested with
Tested in the same studies.
Cilastatin (12) · Relebactam (11) · Amikacin (5) · Tigecycline (4) · Ciprofloxacin (3) · Clofazimine (3) · Linezolid (3) · Trimethoprim, Sulfamethoxazole Drug Combination (2)
Studies
Open first, then newest update. How each study uses Imipenem is read from its arms, and is right about nine times in ten.
Testing it · 30
- Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver TransplantationNot yet recruitingPhase 3IRCCS Azienda Ospedaliero-Universitaria di BolognaNCT07759453Written as Imipenem+Relebactam
- Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary InfectionEnrolling by invitationPhase 1Vancouver Coastal HealthNCT07228702Written as Imipenem + Cilastatin
- Finding the Optimal Regimen for Mycobacterium Abscessus TreatmentRecruitingPhase 2/3The University of QueenslandNCT04310930Written as Imipenem
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform TrialNot yet recruitingPhase 2The University of QueenslandNCT07485010Written as Imipenem + Cilastatin
- PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONINCompletedPhase 2M.D. Anderson Cancer CenterNCT04983901Written as Imipenem/Cilastatin/Relebactam
- Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)CompletedPhase 2/3Merck Sharp & Dohme LLCNCT03969901Written as IMI/REL
- Antimicrobial Treatment in Patients With Ventilator-associated TracheobronchitisTerminatedPhase 4University Hospital, LilleNCT03012360Written as imipenem
- Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)CompletedPhase 3Merck Sharp & Dohme LLCNCT03583333Written as IMI/REL FDC
- Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic FibrosisTerminatedPhase 4Hartford HospitalNCT05561764Written as Imipenem/Cilastatin/Relebactam
- Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU PatientsWithdrawnPhase 4University of Illinois at ChicagoNCT05146154Written as Imipenem/Cilastatin/Relebactam 1.25g
- Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE InfectionsWithdrawnPhase 4Wake Forest University Health SciencesNCT04785924Written as Imipenem+Relebactam
- A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)CompletedPhase 1Merck Sharp & Dohme LLCNCT03230916Written as IMI/REL FDC
- Evaluation of Innovative Tools in Development of AntibioticsCompletedPhase 1Medical University of ViennaNCT03177720Written as Imipenem
- Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)CompletedPhase 3Merck Sharp & Dohme LLCNCT03293485Written as Imipenem+Cilastatin/Relebactam
- Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)CompletedPhase 3Merck Sharp & Dohme LLCNCT02493764Written as Imipenem
- Antibiotic Prophylaxis for Transrectal Prostate BiopsyCompletedPhase 4Northwestern UniversityNCT01659866Written as imipenem
- Imipenem in Critically Ill PatientsStatus unknownPhase 4Prince of Songkla UniversityNCT03776305Written as Imipenem
- Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCTStatus unknownPhase 2/3Nanfang Hospital, Southern Medical UniversityNCT03733340Written as Imipenem
- Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)CompletedPhase 3Merck Sharp & Dohme LLCNCT02452047Written as Imipenem+Cilastatin/Relebactam
- Fosfomycin Plus Imipenem for Treatment of Infective EndocarditisCompletedPhase 4Juan A. ArnaizNCT00871104Written as Fosfomycin and imipenem
See all 30 studies that test Imipenem →
Given in every arm · 6 — Imipenem is usual care beside what is tested
- To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.CompletedPhase 1Evopoint Biosciences Inc.NCT04801043Written as Imipenem/Cilastatin
- A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.Status unknownNot applicableInstitute of Liver and Biliary Sciences, IndiaNCT04208763Written as Imipenem
- A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)CompletedPhase 1Merck Sharp & Dohme LLCNCT01275170Written as Imipenem + Cilastatin
- Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)CompletedPhase 2Merck Sharp & Dohme LLCNCT01506271Written as Imipenem/cilastatin
- Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)CompletedPhase 2Merck Sharp & Dohme LLCNCT01505634Written as imipenem/cilastatin 500 mg
- Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy SubjectsCompletedPhase 1Entasis TherapeuticsNCT02971423Written as Imipenem/Cilastatin
As the comparator · 11 — what is tested is compared with Imipenem
- A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute PyelonephritisNot yet recruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT06144060Written as Imipenem and Cilastatin Sodium
- A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute PyelonephritisCompletedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT06569056Written as Imipenem and Cilastatin Sodium
- Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated PyelonephritisCompletedPhase 3Meiji Seika Pharma Co., Ltd.NCT05887908Written as imipenem/cilastatin
- Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)CompletedPhase 3Evopoint Biosciences Inc.NCT05204563Written as Imipenem/Cilastatin/Relebactam
- A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract InfectionsCompletedPhase 2ShionogiNCT02321800Written as Imipenem/cilastatin
- A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or PneumoniaCompletedPhase 2Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT00515034Written as Imipenem/cilastatin
- Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract InfectionsCompletedPhase 2PfizerNCT00690378Written as Imipenem/Cilastatin
- A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal InfectionCompletedPhase 4PfizerNCT01721408Written as Imipenem/cilastatin
- Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia ColiTerminatedPhase 4Central Hospital, Nancy, FranceNCT02474706Written as imipenem
- Piperacillin/Tazobactam for Empirical Therapy of Febrile NeutropeniaCompletedNot applicableChinese PLA General HospitalNCT01714570Written as Imipenem
- Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired PneumoniaTerminatedPhase 2PfizerNCT00707239Written as imipenem/cilastatin
Codes
What other systems call Imipenem · ClinicalTrials.gg INT008468
- MeSH (NLM) D015378ImipenemConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 71OTZ9ZE0AIMIPENEMConfirmed FDA, NLM, Wikidata
- Wikidata Q27122763imipenem hydrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C570ImipenemOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D015378 | Imipenem | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 71OTZ9ZE0A | IMIPENEM | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27122763 | imipenem hydrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C570 | Imipenem | One source FDA |
Also registered as imipenem anhydrous (UNII Q20IM7HE75 · RxNorm 1545986).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.